Related Experiment Video

Updated: Jan 25, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma

Yun Jung Choi1, Dong Ha Kim1, Dok Hyun Yoon2

  • 1Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.

Scientific Reports
|May 12, 2019
PubMed

Insights

A new drug, QS1189, effectively targets cyclin-dependent kinase 7 (CDK7) to combat aggressive Mantle Cell Lymphoma (MCL) and other lymphomas, even overcoming resistance to existing therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma (NHL) with a poor prognosis, necessitating novel therapeutic strategies.
  • Current treatments, including immunochemotherapy and targeted agents, show limitations in efficacy and overcoming resistance.

Purpose of the Study:

  • To evaluate the anti-cancer potential of QS1189, a novel cyclin-dependent kinase 7 (CDK7) inhibitor, against MCL and other lymphomas.
  • To investigate QS1189's mechanism of action and its efficacy in overcoming acquired drug resistance.

Main Methods:

  • Generation and characterization of QS1189, a selective CDK7 inhibitor.
  • In vitro assessment of QS1189's anti-cancer effects on MCL and lymphoma cell lines.
  • Analysis of QS1189's impact on RNA polymerase II phosphorylation, gene transcription, cell cycle, and apoptosis.
  • Evaluation of QS1189's efficacy in overcoming venetoclax resistance.

Main Results:

  • QS1189 demonstrated potent and selective inhibition of CDK7, with superior anti-cancer effects in MCL compared to ibrutinib and venetoclax.
  • QS1189 treatment reduced RNA polymerase II phosphorylation and transcription of key genes, induced G2/M cell cycle arrest, and promoted apoptosis.
  • QS1189 effectively overcame acquired resistance to venetoclax, which is mediated by Bcl-xL.
  • QS1189 exhibited significant tumor cell growth inhibition across various lymphoma types.

Conclusions:

  • CDK7 is a viable therapeutic target for lymphoma treatment.
  • QS1189 represents a promising therapeutic candidate for diverse lymphomas, including those resistant to current targeted therapies.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

789
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
211
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
618
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.4K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.4K